ConductScience.org, home

Paper366407

The role of cis-platinum in solid-tumor therapy.

Einhorn LH and 1 other. N Engl J Med, 1979. Cited by 186 papers, by iCite.

Cite this record

ConductScience Library. The role of cis-platinum in solid-tumor therapy. Papers, record 366407. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/366407

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The role of cis-platinum in solid-tumor therapy.
PubMed
Journal
N Engl J Med
PubMed
Year
1979
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
186
iCite
Relative citation ratio, by iCite
7.1
iCite
Revised in PubMed
2013-11-21
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Einhorn LHL H
2Williams SDS D

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CisplatinMajor topic
NeoplasmsMajor topic
Age Factors
Antineoplastic Agents
Drug Evaluation
Drug Therapy, Combination
Female
Head and Neck Neoplasms
Humans
Infusions, Parenteral
Injections, Intravenous
Male
Ovarian Neoplasms
Testicular Neoplasms
Urinary Bladder Neoplasms

Source PubMed

Download CSV of topics

Cited by32

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 186 citations.

PMIDTitleJournalYearIn PapersSource
42606259Mechanochemical Sustainable Synthesis of Platinum(II) Complexes: Reactivity Inversion and Coordination Mode Control.Inorg Chem2026https://conductscience.org/library/papers/42606259PubMed
35528662The role of hollow magnetic nanoparticles in drug delivery.RSC Adv2019https://conductscience.org/library/papers/35528662PubMed
34948122New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors.Int J Mol Sci2021https://conductscience.org/library/papers/34948122PubMed
33193881Design and biological evaluation of novel BF-30 analogs for the treatment of malignant melanoma.J Cancer2020https://conductscience.org/library/papers/33193881PubMed
31723194Serum D-serine accumulation after proximal renal tubular damage involves neutral amino acid transporter Asc-1.Sci Rep2019https://conductscience.org/library/papers/31723194PubMed
30733337Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.J Biol Chem2019https://conductscience.org/library/papers/30733337PubMed
29761244Copper-tolfenamic acid: evaluation of stability and anti-cancer activity.Invest New Drugs2019https://conductscience.org/library/papers/29761244PubMed
29177461Rigorous Clinical Trial Design in Public Health Emergencies Is Essential.Clin Infect Dis2018https://conductscience.org/library/papers/29177461PubMed
27350330Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity.Sci Rep2016https://conductscience.org/library/papers/27350330PubMed
23695549Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells.Cancer Res2013https://conductscience.org/library/papers/23695549PubMed
23467445C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin.Clin Med Insights Oncol2013https://conductscience.org/library/papers/23467445PubMed
19629622Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats.Clin Exp Nephrol2009https://conductscience.org/library/papers/19629622PubMed
18542749Should my accountant sing La Traviata at the Met?Can Urol Assoc J2008https://conductscience.org/library/papers/18542749PubMed
8318783Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers.Surg Today1993https://conductscience.org/library/papers/8318783PubMed
8070221Pharmacokinetic drug interactions with anticancer drugs.Clin Pharmacokinet1994https://conductscience.org/library/papers/8070221PubMed
6890414
Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.
Cancer Chemother Pharmacol1982https://conductscience.org/library/papers/6890414PubMed
6687235Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors.J Neurooncol1983https://conductscience.org/library/papers/6687235PubMed
6391659Effect of cis-platinum on human blood monocyte function in vitro.Cancer Immunol Immunother1984https://conductscience.org/library/papers/6391659PubMed
6122510High-dose dexamethasone for prevention of cis-platin-induced vomiting.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/6122510PubMed
6115628Urinary gamma-glutamyl transferase as an indicator of acute nephrotoxicity in rats.Arch Toxicol1981https://conductscience.org/library/papers/6115628PubMed

See all 32 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/366407

GET https://conductscience.org/api/papers/v1/366407/cited_by?page=2